- Fiat Chrysler CEO Marchionne Possibly on Prowl for a Deal With GM
- It's Time for the Eurozone to Let Greece and Tsipras Go
- How Casinos Failed Atlantic City and Why They're Still Part of Its Future
- $15 Minimum Wage Protests Could Spell Major Problem for Retailers
- Five Biggest Losers If LaGuardia Airport Drops Its Perimeter Rule
For investors still cringing at their IRAs, 401(k)s or taxable mutual funds and exchange-traded funds, are you ready to take a chance on the companies that have brought you so many unhappy returns?
The regionals may not have as much recognition as the mammoth securities firms, but they won't be receiving as many unwanted headlines either.
If Pfizer's looking for the next Lipitor, it probably hasn't found it with the acquisition of Wyeth.
Allergan, Mentor and Medicis have struggled in the past year, but if the economy improves, share prices could, too.
When it comes to investing in big pharmaceutical stocks, it's hard to top this company, especially as its peers continue to suffer.
The company continues to wrestle with the dilemma surrounding the drugs Premarin, Prempro and Premphase. Plaintiffs' lawyers have filed approximately 5,400 lawsuits.
In the past five years, its stock has more than tripled, easily outperforming the S&P 500 and the Amex Index of large drug stocks. Is anyone paying attention?
Shares of most major generic-drugmakers have traded below the S&P 500 for the 12 months ended May 23, and that index was off nearly 10%.
Companies such as C.R. Bard and Becton Dickinson might not be the most glamorous names, but their slow and steady performances may win the race.
The companies that supply the tools needed for pharma research and development often profit no matter the success of a drug trial.